India’s pharmaceutical industry has entered an exciting new phase, with exports surging by 9% in 2025, significantly outperforming the global average. According to a recent McKinsey & Company report, India continues to solidify its position as the world’s largest supplier of generic medicines, playing a critical role in global healthcare. In fact, India now supplies 20% of the world’s pharmaceutical demand, including 40% of the United States' generic drug needs and 25% of the United Kingdom’s pharmaceutical market.

One of the key highlights of India’s growing pharma sector is its compliance and manufacturing capabilities. India has surpassed the United States in the number of FDA-approved manufacturing sites, with a total of 752 FDA-approved plants. Additionally, India boasts 2,050 WHO Good Manufacturing Practices (GMP)-certified plants and 286 plants approved by the European Directorate for the Quality of Medicines (EDQM). The improvements in manufacturing standards have led to a 50% reduction in instances of US FDA Official Action Indicated (OAI) cases over the past decade, along with a 27% decrease in non-compliance cases by the European Medicines Agency (EMA).

India’s growth trajectory in the pharmaceutical sector is further fueled by its cost advantage, which is estimated at 30-35% lower than that of US and European manufacturers. This cost benefit is largely due to lower labor costs, enhanced efficiency, and the increasing adoption of digital technologies. India’s pharmaceutical companies have demonstrated exceptional capabilities in both active pharmaceutical ingredients (APIs) and biotechnology, showing an 8% Compound Annual Growth Rate (CAGR). At the same time, advanced treatments such as mRNA therapies, cell and gene therapies, and monoclonal antibodies are growing at an impressive 13-14% CAGR, outpacing conventional drugs.

Artificial Intelligence (AI) is becoming a major factor in the growth of India’s pharmaceutical sector. According to the report, innovations in AI and generative AI could potentially unlock an additional revenue of Rs. 5,23,740 crore to Rs. 9,61,190 crore (US$ 60 billion to US$ 110 billion) for the sector. These innovations are expected to improve margins by 4-7% and boost productivity by 50%, driving even greater efficiency and profitability within the industry.

To further enhance its role in global supply chains, India’s top Contract Development and Manufacturing Organizations (CDMOs) have committed to significant investments, totaling Rs. 56,73 crore (US$ 650 million). These investments are aimed at expanding operations and improving the infrastructure necessary to meet the growing global demand for pharmaceutical products. This underscores India’s growing dominance in the global pharma market, positioning the country as a major player in supplying essential medicines and treatments worldwide.

Despite the positive outlook, the report does acknowledge several challenges that could impact the sector’s future growth. These challenges include digital transformation, the rising trend of nearshoring (bringing production closer to key markets), and increasing demands for sustainability within the pharmaceutical industry. To navigate these challenges and maintain its leadership position, the report suggests that Indian pharmaceutical companies must focus on achieving zero-error operations, adopting AI-driven innovations, optimizing cost structures, and committing to sustainable practices.

Looking ahead, India’s pharmaceutical sector appears poised for continued growth. With a robust manufacturing base, significant investments in AI, and a commitment to quality, India is well-positioned to maintain its role as a global leader in the pharmaceutical industry, ensuring access to affordable medicines across the globe. The future of India’s pharma industry is bright, with the potential for new advancements and growth opportunities paving the way for an even stronger global presence in the years to come.

The Upcoming IPOs in this week and coming weeks are  NAPS Global.

The Current active IPO are Balaji Phosphates, Shreenath Paper.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.

Join our Finance Saathi Telegram Channel for Regular Share Market, News & IPO Update.